TITLE

Nebulised antipseudomonal therapy in cystic fibrosis

AUTHOR(S)
Touw, D. J.; Bakker, W.
PUB. DATE
December 1996
SOURCE
Thorax;Dec1996, Vol. 51 Issue 12, p1283
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
66084924

 

Related Articles

  • Two biotech IPOs make debut. Investor's Business Daily // Investors Business Daily;9/19/2014, pA02 

    Cystic fibrosis therapy developer

  • Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol. Mukhopadhyay, Somnath; Singh, Meenu; Ogston, Simon; Ryan, Gerard; Smyth, Rosalind // Journal of the Royal Society of Medicine (Supplement);Feb1998, Vol. 91 Issue 34, p25 

    The article focuses on a meta-analysis of nebulized antibiotics used in the treatment of cystic fibrosis. The controversy surrounding the nebulized anti-pseudomonal antibiotic therapy for cystic fibrosis is discussed, as well as the characteristics of the randomized controlled trials listed for...

  • Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis. Cheer, Susan M.; Waugh, John; Noble, Stuart // Drugs;2003, Vol. 63 Issue 22, p2501 

    Specifically formulated for nebulisation using the PARI LC PLUS™ reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI[sup ®]] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients...

  • Factors affecting nebulised medicine adherence in adult patients with cystic fibrosis: a qualitative study. Hogan, Alice; Bonney, Mary-Ann; Brien, Jo-anne; Karamy, Rita; Aslani, Parisa // International Journal of Clinical Pharmacy;Feb2015, Vol. 37 Issue 1, p86 

    Background Nebulised medicines contribute to the high treatment burden experienced by patients with cystic fibrosis (CF). Objectives This study explored experiences of adult patients with CF when using nebulised medicines, factors impacting on their adherence to nebulised therapy and strategies...

  • Bronchoconstriction following nebulised colistin in cystic fibrosis. Cunningham, S.; Prasad, A.; Collyer, L.; Carr, S.; Lynn, I. Balfour; Wallis, C. // Archives of Disease in Childhood;May2001, Vol. 84 Issue 5, p432 

    Nebulised colistin is regularly used as antipseudomorial therapy in children with cystic fibrosis. We assessed bronchocon- striction in response to nebulised colistin in 58 children. Nebulised colistin significantly reduced FEV1, MEF25%, and Sao2 for 15 minutes. In 20 children the reduction was...

  • Implementing equipment guidance in the community. Cox, Amanda // Paediatric Nursing;Apr2004, Vol. 16 Issue 3, p28 

    Reports on how Medical Devices Agency (MDA) guidance in Great Britain informed a redesign of the service provided to children with cystic fibrosis who use a nebulised compressor. Objectives for the improvement of the nebuliser service; Key aspect of the implementation of the MDA guidelines;...

  • Emerging Therapies for Respiratory Disease in Cystic Fibrosis. Doherty, Gary M.; Davies, Jane C. // Current Medical Literature: Respiratory Medicine;2008, Vol. 22 Issue 2, p33 

    The article discusses new and emerging therapies for respiratory disease in cystic fibrosis (CF), with an emphasis on developments occurring in the past five years to 2008. In preschool settings, regular anti-staphylococcal treatment is used in many centers as a prophylactic strategy. For...

  • Vehicles for gene therapy. Wilson, James M. // Nature;10/21/1993, Vol. 365 Issue 6448, p691 

    Discusses a report on a trial of cystic fibrosis gene therapy in humans. Use of recombinant adenovirus; Identification of the gene responsible for cystic fibrosis.

  • Gene transfer to airway epithelia. DeWitt, Natalie // Nature Biotechnology;Sep2000, Vol. 18 Issue 9, p914 

    Reports on potential strategy used for treating cystic fibrosis. Replacement of the defective cystic fibrosis transmembrane conductance regulation by gene therapy.

  • ATTEMPTED ERADICATION OF PSEUDOMONAS AERUGINOSA IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS FOLLOWING INTRAVENOUS ANTIBIOTICS AND NEBULISED COLOMYCIN.  // Thorax;Dec2008 Supplement 7, Vol. 63, pA78 

    An abstract of the article "Attempted Eradication of Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis Following Intravenous Antibiotics and Nebulised Colomycin," by J. Stowell and colleagues is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics